Key Segmentation
By Component
-
Software
-
Hardware
-
Services
By Technology
-
Machine Learning
-
Deep Learning
-
Natural Language Processing
-
Others
By Functionality
-
Genome Sequencing
-
Gene Editing
-
Clinical Workflow
-
Predictive Genetic Testing
By Application
-
Drug Discovery and Development
-
Precision Medicine
-
Clinical Diagnostics
-
Others
By End User
-
Pharmaceutical and Biotechnology Companies
-
Clinical Laboratories and Diagnostic Centers
-
Healthcare Providers
-
Academic and Research Institutes
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Artificial Intelligence in Genomics Market was valued at USD 1.39 Billion in 2025 and is estimated at USD 1.86 Billion in 2026. It is projected to reach USD 25.96 Billion by 2035.
The market is expected to grow at a CAGR of 34.01% from 2026 to 2035, supported by falling sequencing costs, national genome programs, and the arrival of genomic foundation models.
North America leads with a 39.56% share in 2025. The region benefits from large research programs, a strong pharmaceutical base, and early clinical use of sequencing.
Asia Pacific is the fastest growing region, with a CAGR of 37.89% through 2035, driven by national genome projects and rising investment in precision medicine.
Software leads by component with 41.55%, machine learning leads by technology with 63.43%, genome sequencing leads by functionality with 44.36%, drug discovery and development leads by application with 33.99%, and pharmaceutical and biotechnology companies lead by end user with 38.22%.